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Abstract
Background: MHC molecules are a highly diverse family of proteins that play a key role in cellular immune recognition.
Over time, different techniques and terminologies have been developed to identify the specific type(s) of MHC molecule
involved in a specific immune recognition context. No consistent nomenclature exists across different vertebrate species.
Purpose: To correctly represent MHC related data in The Immune Epitope Database (IEDB), we built upon a
previously established MHC ontology and created an ontology to represent MHC molecules as they relate to
immunological experiments.
Description: This ontology models MHC protein chains from 16 species, deals with different approaches used to
identify MHC, such as direct sequencing verses serotyping, relates engineered MHC molecules to naturally occurring
ones, connects genetic loci, alleles, protein chains and multi-chain proteins, and establishes evidence codes for MHC
restriction. Where available, this work is based on existing ontologies from the OBO foundry.
Conclusions: Overall, representing MHC molecules provides a challenging and practically important test case
for ontology building, and could serve as an example of how to integrate other ontology building efforts into
web resources.
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Background
Major histocompatibility complex (MHC) proteins play
a central role in the adaptive immune system. First
discovered due to their role in transplant rejection,
MHC molecules are encoded by a large family of genes
with wide variation within each species. MHC molecules
typically bind peptide fragments of proteins and display
them on the cell surface where they are scanned by T
cells of the immune system. If a peptide fragment is
displayed by MHC, it can trigger a T cell immune re-
sponse. Peptides triggering a response are referred to as
‘epitopes’. Thus, binding of epitopes to MHC molecules
is an integral step for immune recognition. The specific
MHC molecule that presents an epitope to a T cell is
knowns as its “MHC restriction”, often called its MHC
restriction (or restricting) element. Accurately representing
this MHC restriction, which can be determined in different
manners, is the goal of the work presented here. Most
MHC molecules consist of two protein chains, of which at
least one gene is present within the MHC locus. In humans
this locus is known as the human leukocyte antigen (HLA)
and is depicted in Fig. 1a. There are thousands of different
allelic variants of these genes coding for different proteins
that result in diverse MHC binding specificities found in
the human population. The most precise way of specifying
MHC restriction is to identify the exact protein chains that
make up the MHC molecule. However, until recently such
exact molecular typing was not possible, and patterns of
antibody binding were utilized to group MHC molecules
together into serotypes that share a common serological
(antibody based) recognition pattern, as shown in Fig. 1b.
Tying such traditional serotype information together with
current sequence based MHC typing techniques is one of
the goals of our study. In yet other cases, such as inbred
mouse strains, MHC restriction is narrowed down based
on the haplotype of the animal, the set of alleles present on
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a single chromosome and thus expressed consistently
together in select subspecies or strains. Another way MHC
restriction is sometimes inferred is based on the T cells rec-
ognizing the epitope. MHC molecules are divided into
three classes: MHC class I, MHC class II, and non-classical
MHC. MHC class I molecules present epitopes to CD8+ T
cells and are made up of one alpha chain and one β2
microglobulin chain, which is invariant and encoded out-
side the MHC locus. MHC class II molecules present epi-
topes to CD4+ T cells and are composed of one alpha and
one beta chain, as shown in Fig. 1c. Thus knowing if the
responding T cell expresses CD4 verses CD8 can be used to
narrow down the possible MHC restriction into classes. At
the same time, current research has identified that
some T cell populations do not follow this pattern exactly
(e.g. some T cells recognizing MHC-II restricted epitopes
express CD8). It is therefore important to capture not only
the inferred restriction information, but also the evidence
upon which it was based.
Methods
The Immune Epitope Database (www.iedb.org) presents
thousands of published experiments describing the rec-
ognition of immune epitopes by antibodies, T cells, or
MHC molecules [1]. The data contained in the IEDB is
primarily derived through manual curation of published
literature, but also includes some directly submitted
data, primarily from NIAID funded epitope discovery
contracts [2]. The goal of the current work was to repre-
sent MHC data as they are utilized by immunologists to
meet the needs of the IEDB users. We collected user
input at workshops, conferences and the IEDB help sys-
tem regarding how they wanted to retrieve data from
the IEDB regarding MHC restriction. These requests
were used to identify goals for this ontology project and
the final ontology was evaluated if it could answer these
requests. As shown in Additional file 1: Table S1, an
example of such a request was to be able to query for
epitopes restricted by MHC molecules with serotype ‘A2’
and retrieve not only serotyped results but also those
where the restriction is finer mapped e.g. to MHC mol-
ecule A*02:01 which has serotype A2. We set out to
logically represent the relationships between the genes
encoding MHC, the haplotypes linking together groups
of genes in specific species, and the individual proteins
comprising MHC complexes, in order to present immuno-
logical data in an exact way and to improve the functional-
ity of our website. Our work builds on MaHCO [3], an
ontology for MHC developed for the StemNet project,
using the well-established MHC nomenclature resources of
the international ImMunoGeneTics information sys-
tem (IMGT, http://www.imgt.org) for human data and
The Immuno Polymorphism Database (IPD, http://
www.ebi.ac.uk/ipd) for non-human species. It contains
Fig. 1 MHC presentation and restriction. a. HLA locus of human chromosome 6 encodes specific MHC protein chains. b. The MHC on APC
presenting epitopes can be bound by antibodies to establish the serotype. c. If responding effector cells are known to be CD4 cells, the MHC
presenting the epitope can be presumed to be class II restricted
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118 terms for MHC across human, mouse, and dog.
We were encouraged by the success of MaHCO in ex-
pressing official nomenclature using logical defini-
tions. However, we needed to extend it for the
purpose of the IEDB to include data from a growing
list of 16 species, as well as data about MHC protein
complexes (not just MHC alleles), haplotypes and se-
rotypes. Thus, our current work goes beyond MaHCO,
and we have utilized this opportunity to also enhance
the integration with other ontological frameworks.
We used the template feature of the open source
ROBOT ontology tool [4] to specify the content of our
ontology in a number of tables. Most of the tables cor-
respond to a single “branch” of the ontology hierarchy,
in which the classes have a consistent logical structure,
e.g. gene loci, protein chains, mutant MHC molecules,
haplotypes, etc. The OWL representation of our ontol-
ogy is generated directly from the tables using ROBOT.
This method enforces the ontology design patterns we
have chosen for each branch, and makes certain editing
tasks easier than with tools such as Protégé.
Results and discussion
Our MHC Restriction Ontology (MRO) is available in a
preliminary state at https://github.com/IEDB/MRO. It is
based on existing ontology terms, including: ‘material
entity’ from the Basic Formal Ontology (BFO) [5], ‘pro-
tein complex’ from The Gene Ontology (GO) [6], ‘pro-
tein’ from The Protein Ontology (PRO) [7], ‘organism’
from The Ontology for Biomedical Investigations (OBI)
[8], ‘genetic locus’ from The Reagent Ontology (REO)
[9], ‘has part’, ‘in taxon’, and ‘gene product of ’ from The
Relation Ontology (RO) [10]. The NCBI Taxonomy was
used to refer to each species [11]. Although it is not yet
complete, we strive to conform to Open Biological and
Biomedical Ontologies (OBO) [12] standards. MRO
currently contains 1750 classes and nearly 9000 axioms,
including more than 2100 logical axioms. Its DL expres-
sivity is “ALEI”, and the HermiT reasoner [13] completes
reasoning in less than 10 seconds on a recent laptop.
Synonyms were also included, as immunologists
often utilize synonyms that are either abbreviations or
based on previous states of the nomenclature. The
current MHC nomenclatures for various species have
been revised through several iterations. In order to
ensure accuracy and remain up to date with the latest
nomenclature, we referred to the well-established
MHC nomenclature resources of the IMGT and IPD.
For specific species where the literature was most
formidable, such as chicken, cattle, and horse, we col-
laborated with experts in these fields. These experts
reviewed the encoded hierarchy by determining whether
the inferred parentage hierarchy in their area of expertise
reflected their input.
Each MHC molecule for which the IEDB has data is
modeled as a protein complex consisting of two chains.
Each chain is a gene product of a specific MHC genetic
locus. For certain species, sub-loci are also defined, when
useful. For example, as shown in Fig. 2 HLA-DPA1*02:01/
DPB1*01:01 consists of one HLA-DPA1*02:01 chain,
encoded by the DPA sub-locus of DP, and one HLA-
DPB1*01:01 chain, encoded by the DPB1 sub-locus of DP.
Together these two chains make up one DPA1*02:01/
DPB1*01:01 MHC molecule.
When the identity of only a single chain of the com-
plex is known, a “generic” second chain is used to
make up the MHC complex. Thus, MHC restriction of
HLA-DPB1*04:02 is modeled as one HLA-DPB1*04:02
chain in complex with an HLA-DPA chain that is not
further specified, as shown within the context of the
hierarchy in Fig. 3.
The data in the ontology drives the Allele Finder on
the IEDB website, available at http://goo.gl/r8Tgrz, an
interactive application that allows users to browse MHC
restriction data in a hierarchical format. We evaluated
the ability of MRO to meet the needs of IEDB users, as
shown in Additional file 1: Table S1, and found it to
meet our initial goals. Currently the use of the ontology
is behind the scenes, but we have requested namespace
and permanent identifiers from The Open Biomedical
Ontologies (OBO). As soon as these identifiers are in
place, they will be utilized and displayed on the IEDB
website to allow users to link out to the ontology.
In MHC binding and elution assays, the exact MHC
molecule studied is typically known; however this is
often not the case for T cell assays. When a T cell re-
sponds to an epitope, the identity of the MHC molecule
presenting the epitope may not be known at all, it may
be narrowed down to a subset of all possible molecules
or it may be exactly identified. In the context of T cell
assays, the MHC restriction can be determined by the
genetic background of the host, conditions of the experi-
ment, or the biological process being measured; there-
fore we represent MHC molecules at a variety of levels
and specify the rationale behind the determined restric-
tion using evidence codes.
As shown in Fig. 4a, IEDB Evidence codes include
“author statement” for cases where authors report pre-
viously defined restriction and “MHC ligand assay”
used for MHC restriction established via an experiment
that demonstrated the ability of the epitope to bind
strongly to the MHC molecule or to have been eluted
from that molecule. Figure 4b shows the metadata asso-
ciated with this evidence code. “MHC binding predic-
tion” is used when computer algorithms are used to
predict the likelihood of an epitope to bind to a specific
MHC molecule. In cases where authors analyze the
MHC phenotype of a study population and conclude a
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likely restriction based upon epitope recognition pat-
terns among the subjects, “statistical association” is
used as the evidence code. We use a set of evidence
codes to communicate restriction shown by the response of
T cells to the epitope: MHC complex. These include “Single
MHC available” for cases where T cells respond to the epi-
tope when only a single MHC molecule is available and “re-
activity of same T cells with different MHC” is used when
different APC expressing different MHC are used to nar-
row the potential restriction. The use of antibodies to block
or purify subsets of MHC molecules typically determines
restriction to an imprecise level, such as HLA-DR and is
conveyed by “set of MHC available.” When the Tcells being
studied are known to be CD8 or CD4 cells, the restriction
can be deduced to be class I or class II, respectively, due to
the known binding pattern of the molecules, as depicted in
Fig. 1c. This case is communicated by the evidence code of
“type of effector T cell.” Lastly, certain T cell responses can
indicate the effector cell phenotype of CD8 or CD4, based
upon known functions of the subsets and thus, class I or II
restriction can be inferred and is noted by the evidence
code of “biological process measured.” Figure 4c shows the
Fig. 2 Ontologic relationships between MRO terms
Fig. 3 Ontological model showing human MHC class II molecules
Vita et al. Journal of Biomedical Semantics  (2016) 7:1 Page 4 of 7
modeling of these evidence codes in terms of the specific
experiments, data transformations performed (using OBI
terms), and the type of conclusion drawn. This work is
being conducted in parallel with the general alignment of
the Evidence Ontology (ECO) [14], which provides succinct
codes for such types of evidence, with OBI, which can
break down how such a code translates to specific experi-
ments performed.
The IEDB MHC Allele Finder application, shown in
Fig. 5, now allows users to browse data in different
views. MHC molecules are first categorized into ‘class
I, class II or non-classical’, and then further subdivided
by species. Within each species, MHC molecules are
organized by genetic locus. For select species, such as
human, there are a large number of MHC molecules
known and studied per genetic locus, thus sub-loci are
also used in order to present the data in a more user-
friendly format. Each MHC molecule is presented
under its locus, its haplotype, and/or its serotype,
when available, all representing newly added function-
alities. The haplotype the host species expresses is
represented as immunologists often rely on the known
haplotypes of research animals to narrow the potential
MHC restriction. For example, when BALB/c (H2d)
mice demonstrate a response to an epitope and the
responding T cells are CD4+, the restricting MHC can
be assumed to be one of the two MHC class II mole-
cules of that haplotype, namely H2 IAd or IEd.
The serotype of an MHC molecule, defined by anti-
body staining patterns, is relevant in immunology as this
was the method of choice to identify MHC molecules
until quite recently. In contrast to molecular definitions
Fig. 4 Evidence codes in MRO
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of MHC molecules based on their specific nucleotide or
amino acid sequence, serotyping classifies MHC mole-
cules based entirely on antibody binding patterns to the
MHC molecule. These patterns are linked to the panel
of antibodies used. Changing the antibody panel changes
the serotype of a molecule. This can result in “serotype
splits” where MHC molecules that were previously con-
sidered identical by one antibody panel, are later found
to actually be two different molecules by a different anti-
body panel. To reflect this extrinsic nature of serotyping,
we refer to serotypes as information entities rather than
physical entities. Alternatively, the concept of serotype
could also be modeled as collections of binding disposi-
tions, but we chose what we thought was the simpler
approach. MHC for all 16 species currently having MHC
data in the IEDB are modeled to give users the ability to
browse the tree in multiple ways and search IEDB data
broadly, by entire MHC class, for example, or narrowly
by a specific MHC protein chain. As new MHC mole-
cules are encountered, they can be easily incorporated
into this ontology.
Conclusions
In conclusion, we formally represented MHC data
building on established ontologies in order to represent
MHC restrictions as required by immunologists. Ac-
cordingly, we modeled MHC molecules as a protein
complex of two chains and established the relationships
between the genes encoding these proteins, the haplo-
types expressed by specific species, and the MHC clas-
ses. Traditional serotype information was also related
to specific MHC molecules. Precise MHC restriction
was conveyed, as well as inferred MHC restriction and
also the experimental evidence upon which the restric-
tion was established. We will continue to formalize this
work and will release a completed interoperable ontol-
ogy later this year. Thus, MHC data in the IEDB is now
presented to its users in a hierarchical format which
simplifies searching the data and additionally instructs
users on the inherent relationships between MHC
genes and MHC restriction.
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